ClinicalTrials.gg
CompletedNCT03345316Updated Dec 11, 2019

Study of FFI-1010 in Pediatric Kidney Disease

A Phase 3 interventional study of FFI-1010 in Children Under 18 Years Old With Kidney Disease, sponsored by Fuji Yakuhin Co., Ltd.. Completed at 1 site in Japan. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2019-12-11.

Sponsored by Fuji Yakuhin Co., Ltd. · Phase 3, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
Up to 18 Years
Sex
All
01

Study summary

The purpose of this study is revealing that the ratio of creatinine clearance (Ccr) to inulin clearance (Cin) measuring at the same time is more than 1.2.

02

Conditions studied

  • Children Under 18 Years Old With Kidney Disease
03

In context

Lead sponsor

Fuji Yakuhin Co., Ltd. is the lead sponsor of 12 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Kidney disease patients requiring exact evaluation of kidney function
  • : >=30 and \<=89 mL/min/1.73m\^2

Exclusion criteria

Exclusion Criteria:

  • Edema on the day before start of study treatment
  • Oliguria on the day before start of study treatment
  • Dehydration on the day before start of study treatment
  • Infection or inflammatory disease before administration
  • History of epilepsy or organic brain disorder
  • History of, cardiac, hematologic, hepatic and pancreatic disease
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    FFI-1010

    Drug: FFI-1010

Interventions

  • DrugFFI-1010

    Intravenous single dosing

06

What researchers measure

Primary outcomes

  1. Ratio of Cin to Ccr measuring at the same time

    Demonstrating usability of inulin clearance by comparison between inulin clearance and creatinine clearance at the same time after the start of FFI-1010 administration

    Time frame: 120 minutes

07

Study locations

1 site
  • Fuji Yakuhin Investigational sites
    Tokyo, Japan
08

References and documents

Publications

  • Uemura O, Ishikura K, Kamei K, Hamada R, Yamamoto M, Gotoh Y, Fujita N, Sakai T, Sano T, Fushimi M, Iijima K. Comparison of inulin clearance with 2-h creatinine clearance in Japanese pediatric patients with renal disease: open-label phase 3 study of inulin. Clin Exp Nephrol. 2022 Feb;26(2):132-139. doi: 10.1007/s10157-021-02133-5. Epub 2021 Sep 25. PubMed 34562149 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2017 to primary completion in Nov 2019, 24 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2017
First posted
Nov 17, 2017
StartActual
Nov 1, 2017
Primary completionActual
Nov 1, 2019
CompletionActual
Nov 1, 2019
Last update
Dec 11, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03345316
Lead sponsor
Fuji Yakuhin Co., Ltd.
Responsible party
Sponsor
First posted
Nov 17, 2017
Start date
Nov 1, 2017
Primary completion
Nov 1, 2019
Completion
Nov 1, 2019
Last update
Dec 11, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion